NYSE:BCR - C R Bard Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$331.24Today's Range$331.24 - $331.2452-Week Range$222.42 - $337.73VolumeN/AAverage Volume679,456 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs. Receive BCR News and Ratings via Email Sign-up to receive the latest news and ratings for BCR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry N/A Sub-IndustryHealth Care Equipment SectorN/A Current SymbolNYSE:BCR Previous Symbol CUSIP06738310 CIK9892 Webwww.crbard.com Phone+1-908-2778000Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable C R Bard (NYSE:BCR) Frequently Asked Questions What is C R Bard's stock symbol? C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR." How were C R Bard's earnings last quarter? C R Bard Inc (NYSE:BCR) posted its quarterly earnings results on Wednesday, October, 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.06. The medical instruments supplier earned $989.80 million during the quarter, compared to analyst estimates of $990.64 million. The business's revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.64 earnings per share. View C R Bard's Earnings History. Has C R Bard been receiving favorable news coverage? News stories about BCR stock have trended negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. C R Bard earned a daily sentiment score of -2.7 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. What other stocks do shareholders of C R Bard own? Based on aggregate information from My MarketBeat watchlists, some companies that other C R Bard investors own include Abbott Laboratories (ABT), Becton Dickinson and (BDX), Johnson & Johnson (jnj), Intuitive Surgical (ISRG), AbbVie (ABBV), Medtronic (MDT), Baxter International (bax), Bristol-Myers Squibb (BMY), Boston Scientific (BSX) and Amgen (AMGN). Who are C R Bard's key executives? C R Bard's management team includes the folowing people: Timothy M. Ring, Chairman of the Board, Chief Executive Officer (Age 59)John H. Weiland, President, Vice Chairman of the Board, Chief Operating Officer (Age 61)James C. Beasley, Group President (Age 53)Timothy P. Collins, Group President (Age 56)John P. Groetelaars, Group President (Age 50)Christopher S. Holland, Chief Financial Officer, Senior Vice President (Age 50)Samrat S. Khichi, Senior Vice President, General Counsel, Secretary (Age 49)John A. DeFord Ph.D., Senior Vice President - Science, Technology and Clinical Affairs (Age 55)Frank Lupisella Jr., Vice President, Controller (Age 56)Betty D. Larson, Vice President - Human Resources (Age 41) What is C R Bard's official website? The official website for C R Bard is https://www.crbard.com. How can I contact C R Bard? C R Bard's mailing address is 730 Central Ave, NEW PROVIDENCE, NJ 07974-1139, United States. The medical instruments supplier can be reached via phone at +1-908-2778000. MarketBeat Community Rating for C R Bard (NYSE BCR)Community Ranking: 1.8 out of 5 ()Outperform Votes: 338 (Vote Outperform)Underperform Votes: 577 (Vote Underperform)Total Votes: 915MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe BCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BCR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Return on Investment (ROI) Defined, Explained Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.